Terbinafine-DRLA terbinafine (as hydrochloride) 250 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

terbinafine-drla terbinafine (as hydrochloride) 250 mg tablet blister pack

dr reddys laboratories australia pty ltd - terbinafine hydrochloride, quantity: 281.25 mg (equivalent: terbinafine, qty 250 mg) - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate - treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

APO-TERBINAFINE terbinafine 250mg (as hydrochloride) tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-terbinafine terbinafine 250mg (as hydrochloride) tablet blister pack

arrotex pharmaceuticals pty ltd - terbinafine hydrochloride, quantity: 281.3 mg (equivalent: terbinafine, qty 250 mg) - tablet, uncoated - excipient ingredients: methylcellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica - apo-terbinafine is indicated for: treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infections caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

Pentothal thiopental sodium 500 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

pentothal thiopental sodium 500 mg powder for injection vial

link medical products pty ltd t/a link pharmaceuticals - thiopental sodium, quantity: 0.5 g - injection, powder for - excipient ingredients: - indications as at 08 dec 1993 : pentothal may be used : 1. as the sole anaesthetic agent for brief surgical procedures; 2. for the induction of anaesthesia prior to the administration of other anaesthetic agents; 3. for the short-term control of condvulsive states; 4. to supplement regional anaesthesia or low potency agents such as nitrous oxide.

SYMMETREL 100  amantadine hydrochloride 100mg capsule bottle Australia - English - Department of Health (Therapeutic Goods Administration)

symmetrel 100 amantadine hydrochloride 100mg capsule bottle

novartis pharmaceuticals australia pty ltd - amantadine hydrochloride, quantity: 100 mg - capsule, soft - excipient ingredients: titanium dioxide; glycerol; lecithin; sodium propyl hydroxybenzoate; yellow beeswax; partially hydrogenated soya oil; iron oxide red; gelatin; sodium ethyl hydroxybenzoate; hydrogenated soya oil; rape seed oil; maize starch; sorbitol; mannitol; ethyl acetate; butan-1-ol; shellac; industrial methylated spirit - parkinson's disease: idiopathic parkinson's disease; post encephalitic parkinsonism; symptomatic parkinsonism (e.g. following cns injury from carbon monoxide poisoning); arteriosclerotic parkinsonism; drug-induced extrapyramidal reactions. symmetrel can be given alone for initial therapy or combined with anticholinergic drugs or l-dopa (see "dosage and administration"). note: symmetrel is not indicated for the treatment of tardive dyskinesia. type a virus influenza: prophylaxis of respiratory tract illness caused by influenza type a. prophylaxis in non-immunized individuals (including children) for whom influenza may have serious consequences (e.g. persons with chronic respiratory disease of diabetes mellitus).

Voluven New Zealand - English - Medsafe (Medicines Safety Authority)

voluven

fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons); sodium chloride 0.9%; hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) - solution for infusion - active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) sodium chloride 0.9% excipient: hydrochloric acid sodium hydroxide water for injection active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

PAROXETINE GH paroxetine (as hydrochloride) 20mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

paroxetine gh paroxetine (as hydrochloride) 20mg tablet blister pack

sandoz pty ltd - paroxetine hydrochloride, quantity: 22.2 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; magnesium stearate; copovidone; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; sodium starch glycollate; purified talc - paroxetine gh is indicated for the treatment of : - major depression and for the prevention of relapse of depressive symptoms - obsessive compulsive disorder (ocd) and prevention of relapse of ocd - panic disorder and for the prevention of relapse of panic disorder - social anxiety disorder/social phobia - general anxiety disorder - post-traumatic stress disorder.

OMEGAPHARM THIOPENTAL SODIUM 470  mg thiopental sodium 470 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm thiopental sodium 470 mg thiopental sodium 470 mg powder for injection vial

omegapharm - thiopental sodium, quantity: 470 mg - injection, powder for - excipient ingredients: - ? as the sole anaesthetic agent for brief surgical procedures.,? induction of anaesthesia prior to the administration of other anaesthetic agents.,? short-term control of convulsive states.,? supplement to regional anaesthesia or low potency agents such as nitrous oxide.

TERBINAFINE ARW terbinafine (as hydrochloride) 250 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

terbinafine arw terbinafine (as hydrochloride) 250 mg tablet blister pack

arrotex pharmaceuticals pty ltd - terbinafine hydrochloride, quantity: 281.28 mg - tablet, uncoated - excipient ingredients: hypromellose; colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate - ? treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. ? onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

APO-MEMANTINE memantine hydrochloride 20mg film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-memantine memantine hydrochloride 20mg film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - memantine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: hyprolose; iron oxide red; iron oxide yellow; microcrystalline cellulose; hypromellose; methylcellulose; magnesium stearate; macrogol 8000; titanium dioxide; croscarmellose sodium - treatment of the symptoms of moderately severe to severe alzheimer's disease (see pharmacology, precautions).